Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 7.78
(3.87%)
CNY 7.78
(3.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -398.89 Million CNY | -102.48% |
| 2022 | -197 Million CNY | -43.38% |
| 2021 | -137.4 Million CNY | -3.29% |
| 2020 | -133.01 Million CNY | -587.26% |
| 2019 | 27.29 Million CNY | -79.64% |
| 2018 | 134.05 Million CNY | -49.03% |
| 2017 | 263.02 Million CNY | 2.24% |
| 2016 | 257.27 Million CNY | 21.89% |
| 2015 | 211.07 Million CNY | 8.09% |
| 2014 | 195.27 Million CNY | 78.22% |
| 2013 | 109.57 Million CNY | -31.62% |
| 2012 | 160.23 Million CNY | 53.69% |
| 2011 | 104.25 Million CNY | 81.32% |
| 2010 | 57.49 Million CNY | 62.6% |
| 2009 | 35.36 Million CNY | 115.32% |
| 2008 | 16.42 Million CNY | 336.61% |
| 2007 | 3.76 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 346.38 Thousand CNY | 109.19% |
| 2024 Q3 | -5.94 Million CNY | -1815.41% |
| 2024 Q1 | -3.76 Million CNY | 98.24% |
| 2023 FY | -398.89 Million CNY | -102.48% |
| 2023 Q1 | -48.72 Million CNY | -15.64% |
| 2023 Q2 | -104.7 Million CNY | -114.9% |
| 2023 Q4 | -213.92 Million CNY | -578.27% |
| 2023 Q3 | -31.53 Million CNY | 69.88% |
| 2022 Q4 | -42.13 Million CNY | 41.58% |
| 2022 FY | -197 Million CNY | -43.38% |
| 2022 Q1 | -24.4 Million CNY | -110.63% |
| 2022 Q2 | -58.33 Million CNY | -138.99% |
| 2022 Q3 | -72.12 Million CNY | -23.64% |
| 2021 Q2 | -39.9 Million CNY | -100.44% |
| 2021 Q1 | -19.9 Million CNY | 42.78% |
| 2021 FY | -137.4 Million CNY | -3.29% |
| 2021 Q4 | -11.58 Million CNY | 82.44% |
| 2021 Q3 | -65.99 Million CNY | -65.4% |
| 2020 FY | -133.01 Million CNY | -587.26% |
| 2020 Q4 | -34.79 Million CNY | -49.63% |
| 2020 Q3 | -23.25 Million CNY | 53.72% |
| 2020 Q2 | -50.24 Million CNY | -103.09% |
| 2020 Q1 | -24.73 Million CNY | -79.2% |
| 2019 FY | 27.29 Million CNY | -79.64% |
| 2019 Q3 | 5.4 Million CNY | -30.41% |
| 2019 Q4 | -13.8 Million CNY | -355.39% |
| 2019 Q2 | 7.76 Million CNY | -72.19% |
| 2019 Q1 | 27.93 Million CNY | 83.67% |
| 2018 FY | 134.05 Million CNY | -49.03% |
| 2018 Q1 | 55.57 Million CNY | 42.42% |
| 2018 Q4 | 15.2 Million CNY | -31.07% |
| 2018 Q3 | 22.06 Million CNY | -46.46% |
| 2018 Q2 | 41.21 Million CNY | -25.85% |
| 2017 Q4 | 39.02 Million CNY | -52.08% |
| 2017 Q1 | 68.05 Million CNY | 25.43% |
| 2017 Q2 | 74.5 Million CNY | 9.47% |
| 2017 Q3 | 81.44 Million CNY | 9.31% |
| 2017 FY | 263.02 Million CNY | 2.24% |
| 2016 FY | 257.27 Million CNY | 21.89% |
| 2016 Q1 | 54.92 Million CNY | 44.66% |
| 2016 Q4 | 54.26 Million CNY | -35.9% |
| 2016 Q2 | 63.43 Million CNY | 15.51% |
| 2016 Q3 | 84.65 Million CNY | 33.44% |
| 2015 Q3 | 63.81 Million CNY | 8.44% |
| 2015 FY | 211.07 Million CNY | 8.09% |
| 2015 Q4 | 37.96 Million CNY | -40.51% |
| 2015 Q2 | 58.84 Million CNY | 16.66% |
| 2015 Q1 | 50.44 Million CNY | -29.65% |
| 2014 Q4 | 71.7 Million CNY | 13.53% |
| 2014 FY | 195.27 Million CNY | 78.22% |
| 2014 Q1 | 35.57 Million CNY | 781.25% |
| 2014 Q2 | 24.84 Million CNY | -30.15% |
| 2014 Q3 | 63.15 Million CNY | 154.2% |
| 2013 Q3 | 18.35 Million CNY | -62.17% |
| 2013 Q4 | -5.22 Million CNY | -128.45% |
| 2013 FY | 109.57 Million CNY | -31.62% |
| 2013 Q1 | 47.92 Million CNY | 37.24% |
| 2013 Q2 | 48.51 Million CNY | 1.23% |
| 2012 Q1 | 37.04 Million CNY | -19.6% |
| 2012 Q4 | 34.91 Million CNY | 0.65% |
| 2012 Q2 | 53.58 Million CNY | 44.66% |
| 2012 Q3 | 34.69 Million CNY | -35.25% |
| 2012 FY | 160.23 Million CNY | 53.69% |
| 2011 Q1 | 11.57 Million CNY | -40.31% |
| 2011 FY | 104.25 Million CNY | 81.32% |
| 2011 Q3 | 25.65 Million CNY | 22.43% |
| 2011 Q4 | 46.06 Million CNY | 79.57% |
| 2011 Q2 | 20.95 Million CNY | 81.02% |
| 2010 Q2 | 13.01 Million CNY | 1.71% |
| 2010 FY | 57.49 Million CNY | 62.6% |
| 2010 Q3 | 12.41 Million CNY | -4.62% |
| 2010 Q1 | 12.79 Million CNY | 0.0% |
| 2010 Q4 | 19.39 Million CNY | 56.25% |
| 2009 FY | 35.36 Million CNY | 115.32% |
| 2008 FY | 16.42 Million CNY | 336.61% |
| 2007 FY | 3.76 Million CNY | 0.0% |